X

Trial Profile

A Phase 1b/2 Randomized Study of AVB-S6-500 Plus Nab-paclitaxel and Gemcitabine in Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 01 Nov 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Batiraxcept (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary)
Indications Adenocarcinoma; Pancreatic cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Aravive

Most Recent Events

26 Oct 2023 Status changed from recruiting to discontinued.
28 Jul 2023 According to Aravive media release, data from this trial will be presented at the European Society for Medical Oncology (ESMO) Congress 2023
06 Jun 2023 Results (n=21, as of data cut off date of January 17, 2023) presented at the 59th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com